SynthesisFrontiers in nutrition2025
Docosahexaenoic acid supplementation in phenylketonuria: a systematic review.
Synthesis in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Phenylketonuria (PKU) is an inborn error of metabolism requiring a protein-restricted diet, which may predispose patients to deficiencies in long-chain polyunsaturated fatty acids (LC-PUFAs), particularly docosahexaenoic acid (DHA). Given the critical role of DHA in neurodevelopment and membrane function, supplementation has been proposed as a potential therapeutic adjunct in PKU. To systematically review clinical and biochemical outcomes associated with DHA supplementation in individuals with PKU. Methods: A systematic literature search was conducted in PubMed for studies published between January 1990 and July 2025. We included clinical trials, cohort studies, and observational studies assessing the effects of DHA or LC-PUFA supplementation in PKU. Data were extracted regarding study design, sample size, age, dosage, duration, and outcome measures. Risk of bias was assessed using the Cochrane tool and ROBINS-I as appropriate. Results: A total of 18 studies met the inclusion criteria. DHA supplementation consistently increased erythrocyte and plasma DHA levels, and some trials reported improvements in visual evoked potentials, while cognitive outcomes remained inconsistent. No adverse effects were reported. Conclusion: DHA supplementation appears to be a safe and effective strategy to correct LC-PUFA deficiency in PKU, with potential neurophysiological benefits. However, its impact on long-term neurocognitive development remains uncertain, and further high-quality studies are needed to clarify its clinical value.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.